Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
MYELOMA BIOLOGY AND THERAPY - PRESENT STATUS AND FUTURE-DEVELOPMENTS
Autore:
NISHIMOTO N; SHIMA Y; YOSHIZAKI K; KISHIMOTO T;
Indirizzi:
OSAKA UNIV,SCH MED,DEPT MED 3,2-2 YAMADA OKA OSAKA 565 JAPAN OSAKA UNIV,SCH MED,DEPT MED 3 OSAKA 565 JAPAN OSAKA UNIV,SCH HLTH & SPORT SCI,DEPT MED SCI 1 OSAKA JAPAN
Titolo Testata:
Hematology/oncology clinics of North America
fascicolo: 1, volume: 11, anno: 1997,
pagine: 159 -
SICI:
0889-8588(1997)11:1<159:MBAT-P>2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN MULTIPLE-MYELOMA; TRANS-RETINOIC ACID; MARROW TRANSPLANTATION THERAPY; LEUKEMIA INHIBITORY FACTOR; RANDOMIZED CLINICAL-TRIAL; AUTOLOGOUS BONE-MARROW; NECROSIS FACTOR-ALPHA; PLASMA-CELL LEUKEMIA; TUMOR STEM-CELL; MONOCLONAL-ANTIBODY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
86
Recensione:
Indirizzi per estratti:
Citazione:
N. Nishimoto et al., "MYELOMA BIOLOGY AND THERAPY - PRESENT STATUS AND FUTURE-DEVELOPMENTS", Hematology/oncology clinics of North America, 11(1), 1997, pp. 159

Abstract

Recent progress in cytokine studies has made it possible to understand the pathophysiological roles of cytokines in multiple my-eloma. Specifically, interleukin (IL)-6 is a potent growth factor for myeloma cells and is also responsible for the progressive bone resorption characteristic of this disease. On the basis oi: this evidence, clinical trials to interfere with IL-6 signals have been initiated for the treatment of patients with advanced myeloma. Such a new therapeutic approach as well as myeloblative therapy should be able to provide us with the breakthrough needed to prevail over this so far incurable disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/07/20 alle ore 07:51:31